Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Unity Biotechnology Inc
(NQ:
UBX
)
1.540
-0.010 (-0.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Unity Biotechnology Inc
UNITY Biotechnology to Participate in Upcoming Investor Conferences
August 12, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
August 06, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Reports Granting of New Employment Inducement Award
July 24, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
July 22, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
May 14, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
April 25, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
April 23, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
April 15, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
February 06, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
December 12, 2023
Topline 16-week data expected in the fourth quarter of 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
November 13, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
November 10, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
September 27, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
August 08, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
June 21, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
May 09, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
April 24, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
April 23, 2023
Program Update with retinal expert and senior clinical advisor Robert B. Bhisitkul, M.D., Ph.D., to be held on Monday, April 24 at 5:00 a.m. PT/8:00 a.m. ET
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
March 27, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
March 15, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference
February 15, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study
February 09, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Reports Granting of New Employment Inducement Award
January 18, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates
November 08, 2022
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
November 01, 2022
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
October 31, 2022
Program Update with retinal expert Arshad M. Khanani, M.D., M.A., FASRS, to be held on Tuesday, November 1 at 5:00 a.m. PT/8:00 a.m. ET
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today
October 19, 2022
UBX common stock expected to begin trading on a split-adjusted basis on October 20, 2022
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye
October 11, 2022
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Braeden Lichti: The Business of Anti-Aging and Rejuvenation Biotechnology
December 31, 2021
VANCOUVER, British Columbia - Dec. 31, 2021 - PRLog -- 2020-07-30: Scientists now have a better understanding into the aging process, giving us a better explanation of the cellular changes that lead...
Via
PRLog
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.